Drug intelligence / Profile preview

savolitinib + itraconazole

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

**Savolitinib + itraconazole** is a combination of two orally administered small molecule drugs: savolitinib, a selective inhibitor of the receptor tyrosine kinase MET, and itraconazole, a triazole antifungal and potent CYP3A4 and P-glycoprotein inhibitor. This combination has been investigated in clinical pharmacokinetic studies to assess drug–drug interactions, specifically the effect of itraconazole-mediated CYP3A4 inhibition on the exposure of savolitinib. The addition of itraconazole does not significantly alter the pharmacokinetic profile or overall exposure (Cmax, AUC) of savolitinib, suggesting no clinically significant interaction for this combination.

Other names: savolitinib + itraconazole

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on savolitinib + itraconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on savolitinib + itraconazole.

Explore the full profile